Clinical Implications of Hormonal Dysfunction in ARFID

The findings from Trolio et al.’s longitudinal study provide critical insights for clinicians managing youth with ARFID, especially those exhibiting lack of interest in eating. Recognizing that hormonal dysfunction—specifically elevated CCK and reduced ghrelin—may contribute to this presentation enables practitioners to better tailor their treatment approaches. As there are currently no standardized pharmacologic treatments for ARFID, these hormonal pathways present an avenue for further research and potential intervention strategies. Monitoring patients’ hormonal levels could guide treatment decisions and the development of personalized approaches, potentially including the use of agents that modulate these hormonal pathways. This focus on the biological bases of eating behaviors may help bridge the gap between psychological interventions and physiological needs, leading to more effective management of ARFID and improved quality of life for affected youth.